An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.

被引：4
|
作者：
Boissel, Nicolas
de Botton, Stephane
Thomas, Xavier G.
Rao, Ercole
Bonnevaux, Helene
Rubin-Carrez, Chantal
Guerif, Stephane
Beys, Eric
Gosselin, Alice
Bauchet, Anne-Laure
Novikov, Valery
Fernandes, Elma
Wiederschain, Dmitri
Palatinsky, Emanuel A.
Hsu, Karl
Fraenkel, Paula Goodman
机构：
[1] Hop St Louis, Paris, France
[2] Inst Gustave Roussy, INSERM, U1170, Villejuif, France
[3] Ctr Hosp Lyon Sud, Lyon, France
[4] Sanofi, Frankfurt, Germany
[5] Sanofi, Vitry Sur Seine, France
[6] Sanofi, Alfortville, France
[7] Sanofi, Bridgewater, NJ USA
[8] Sanofi, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS7076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7076
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product in a First-in-Human Trial (PALL) in Pediatric Patients with CD19+Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Qasim, Waseem
    Ciocarlie, Oana
    Adams, Stuart
    Inglott, Sarah
    Murphy, Claire
    Rivat, Christine
    Wright, Gary
    Lucchini, Giovanna
    Silva, Juliana
    Rao, Kanchan
    Zinai, Amina
    Binlich, Florence
    Dupouy, Sandra
    Pauly, Jeanne
    Balandraud, Svetlana
    Dubois, Frederic
    Konto, Cyril
    Patel, Premal
    Chiesa, Robert
    Samarasinghe, Sujith
    Hara, Havinder
    Boyle, Alayna
    Chu, Jan
    Pinner, Danielle
    Amrolia, Persis J.
    Vora, Ajay
    Rao, Anupama
    Ancliffe, Philip
    Veys, Paul
    BLOOD, 2017, 130
  • [22] Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Graham, Charlotte
    Yallop, Deborah
    Jozwik, Agnieszka
    Patten, Piers
    Dunlop, Alan
    Ellard, Rose
    Stewart, Orla
    Potter, Victoria
    Metaxa, Victoria
    Kassam, Shireen
    Farzaneh, Farzin
    Devereux, Stephen
    Pagliuca, Antonio
    Zinai, Amina
    Binlich, Florence
    Dupouy, Sandra
    Philippe, Anne
    Balandraud, Svetlana
    Dubois, Frederic
    Konto, Cyril
    Patel, Premal
    Mufti, Ghulam
    Benjamin, Reuben
    BLOOD, 2017, 130
  • [23] Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Subklewe, Marion y
    Stein, Anthony
    Walter, Roland B.
    Bhatia, Ravi
    Wei, Andrew H.
    Ritchie, David
    Bucklein, Veit
    Vachhani, Pankit
    Dai, Tian
    Hindoyan, Antreas
    Agarwal, Suresh
    Anderson, Abraham
    Khaldoyanidi, Sophia
    Ravandi, Farhad
    BLOOD, 2019, 134
  • [24] Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Assi, Rita
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Jabbour, Elias
    Jain, Nitin
    Daver, Naval
    Estrov, Zeev
    Uehara, Taisuke
    Owa, Takashi
    Cortes, Jorge E.
    Borthakur, Gautam
    CANCER, 2018, 124 (13) : 2758 - 2765
  • [25] CD19-CAR-T Therapy Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed and High Risk B-Cell Acute Lymphoblastic Leukemia
    Zhao, Yanli
    Zhang, Jianping
    Liu, Deyan
    Xiong, Min
    Wei, Zhijie
    Sun, Ruijuan
    Zhou, Jiarui
    Lu, Yue
    Cao, Xingyu
    Yang, Junfang
    Zhang, Xian
    Wang, Hui
    Liu, Hongxing
    Lu, Peihua
    Lu, Daopei
    BLOOD, 2018, 132
  • [26] A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma
    Murthy, Guru Subramanian Guru
    Kearl, Tyce J.
    Cui, Weiguo
    Johnson, Bryon
    Hoffmeister, Karin
    Szabo, Aniko
    Aoki, Kazuhiro
    Harrington, Alexandra M.
    Carlson, Karen
    Michaelis, Laura C.
    Runaas, Lyndsey
    Abedin, Sameem
    Duvall, Adam S.
    Stock, Wendy
    Shah, Bijal D.
    Leonard, Jessica
    Pratz, Keith W.
    Luger, Selina M.
    Badar, Talha
    Baim, Arielle
    Yaghoubi, Shahriar
    Atallah, Ehab L.
    BLOOD, 2021, 138
  • [27] BLINATUMOMAB IMPROVED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY (TOWER)
    Topp, M. S.
    Stein, A.
    Goekbuget, N.
    Fielding, A.
    Schuh, A.
    Ribera Santasusana, J. M.
    Wei, A.
    Dombret, H.
    Foa, R.
    Bassan, R.
    Arslan, O.
    Sanz, M. A.
    Bergeron, J.
    Demirkan, F.
    Lech-Maranda, E.
    Rambaldi, A.
    Thomas, X.
    Fleishman, A.
    Nagorsen, D.
    Holland, C.
    Zimmerman, Z.
    Kantarjian, H.
    HAEMATOLOGICA, 2016, 101 : 24 - 25
  • [28] Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia
    Huang, Liang
    Wang, Na
    Li, Chunrui
    Cao, Yang
    Xiao, Yi
    Xiao, Min
    Zhang, Yicheng
    Zhang, Tongcun
    Zhou, Jianfeng
    BLOOD, 2017, 130
  • [29] Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial
    Jiang, Huiwen
    Li, Chenggong
    Yin, Ping
    Guo, Tao
    Liu, Lin
    Xia, Linghui
    Wu, Yaohui
    Zhou, Fen
    Ai, Lisha
    Shi, Wei
    Lu, Xuan
    Wang, Huafang
    Tang, Lu
    Wei, Qiuzhe
    Deng, Jun
    Jin, Runming
    Xiong, Wei
    Dong, Jian
    Mei, Heng
    Hu, Yu
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (10) : 1113 - 1122
  • [30] Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir T Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Watts, Justin
    Maris, Michael
    Lin, Tara L.
    Patel, Prapti
    Madanat, Yazan F.
    Cogle, Christopher R.
    Borthakur, Gautam
    Huebner, Dirk
    Khaskhely, Noor
    Bonham, Lynn
    Massaro, Monica
    Taylor, Daphne
    Taromino, Caroline
    Mims, Alice S.
    BLOOD, 2022, 140 : 6204 - 6205
12345